AZ-ETHISPHERE
15.3.2022 11:02:14 CET | Business Wire | Press release
Ethisphere, a global leader in defining and advancing the standards of ethical business practices, today announced the 136 honorees representing 22 countries and 45 industries that have earned the coveted designation of World’s Most Ethical Companies® in 2022 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005079/en/
This is the 16th annual recognition of companies that have demonstrated a commitment to ethical business practices through programs that positively impact employees, communities, and broader stakeholders, and contribute to sustainable and profitable long-term business performance.
In 2022, 14 companies are first-time honorees, while six have been recognized 16 times – every year since the inception of the awards in 2007.
“The moment is now, and the data is clear – companies must lead on sustainability, social issues, and governance. The World’s Most Ethical Companies understand that the capitalism of today and tomorrow is one that demonstrates how we turn our ideals into action,” said Ethisphere CEO, Timothy Erblich . “Congratulations to the 2022 honorees for their dedication to advancing business integrity, for leadership on tough issues, and demonstrating that doing good is key to successful, long-term performance.”
“At TIAA, transparency, accountability, and integrity are values deeply embedded in our culture,” said Thasunda Brown Duckett, President and CEO of TIAA . “We know our clients want to work with a partner they trust, and we work hard to do right by them, our employees, and our communities. We’re honored to be named one of the World’s Most Ethical Companies by Ethisphere for the eighth straight year.”
“Recognition for the 14th time as one of the World’s Most Ethical Companies is an incredible honor for which we credit our 400,000 green apron partners (employees) who show up with a common mission,” said Kevin Johnson, president and ceo, Starbucks Coffee Company. “At Starbucks, we know we have to earn the trust we have from our partners, customers, and communities each day by leading with a purpose that goes well beyond the pursuit of profit.”
“It’s a true honor to be named as one of the World’s Most Ethical Companies for the 9th consecutive year,” said Steve James, CEO of Teachers Mutual Bank Limited . “As one of only five banks across the globe to be honored this year, this recognition reinforces our credentials as a socially responsible bank seeking to make a difference. I’m proud to lead a company that is using banking as a force for good.”
Ethisphere’s 2022 Ethics Index, the collection of publicly traded companies recognized as recipients of this year’s World’s Most Ethical Companies designation, outperformed a comparable index of large-cap companies by 24.6 percentage points over the past five calendar years.
“The outperformance, which Ethisphere refers to as the Ethics Premium , has remained consistent since we began tracking the equity performance of honoree companies. We believe this outperformance is the result of the kinds of practices that lead a company to be on our list – practices that demonstrate investment in their people, culture, and communities. We see in this data that those practices, over time, lead to stronger financial performance,” Erblich added.
Ethisphere will host a Virtual Honoree Gala on April 12, 2022. It will feature keynote addresses by Matthew McConaughey, Academy Award® –winning actor, New York Times bestselling author, and founder of the just keep livin Foundation ; and Ernie Johnson , six-time Sports Emmy Award winner, and New York Times bestselling author of Unscripted: The Unpredictable Moments that Make Life Extraordinary .
Methodology & Outcomes
Grounded in Ethisphere’s proprietary Ethics Quotient® , the World’s Most Ethical Companies assessment process includes more than 200 data points on culture; environmental and social practices; ethics and compliance activities; governance; diversity, equity, and inclusion; and initiatives that support a strong value chain. The process serves as an operating framework to capture and codify the leading practices of organizations across industries and around the globe.
This year, the evaluation was updated to include questions inquiring about programmatic changes made in response to the continuing COVID-19 pandemic. It also included a new area around risk assessment, to better address the U.S. Department of Justice’s recent focus on effectiveness of a company’s risk assessment efforts; more detailed questions around key impact assessment processes; and a range of other updates to reflect the evolving landscape as it relates to those in ethics, compliance, and governance.
All companies that participate in the assessment process receive an Analytical Scorecard that provides insights into key trends among honoree companies, and where their programs stand compared to the class of honoree companies. Applicants also receive a three-month Associate membership to the Business Ethics Leadership Alliance (BELA).
Honorees
The full list of the 2022 World’s Most Ethical Companies can be found at https://worldsmostethicalcompanies.com/honorees/ .
Follow the conversation on Twitter: 2022 #WorldsMostEthicalCompanies.
About Ethisphere
Ethisphere® is the global leader in defining and advancing the standards of ethical business practices that fuel corporate character, marketplace trust, and business success. Ethisphere has deep expertise in measuring and defining core ethics standards using data-driven insights that help companies enhance corporate character and measure and improve culture. Ethisphere honors superior achievement through its World’s Most Ethical Companies recognition program and provides a community of industry experts with the Business Ethics Leadership Alliance (BELA). https://ethisphere.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
